Mostrando 2 resultados de: 2
An integral vision of the pharmacology of sodium/glucose co-transporter inhibitors: Past, present, and future
ArticleAbstract: The search for new alternatives for the treatment of diabetes mellitus (DM) has taken a center rolePalabras claves:Clinical pharmacology, diabetes mellitus, Gliflozins, SGLT1, SGLT2Autores:Adame F.T., Alex Patricio Morales Carrasco, Arévalo J.M., Bohórquez F.B., Cataña C.G., Intriago J.A., María Belén Gutiérrez Yépez, Paladines F.M., Quezada P.O.Fuentes:scopusCanaaliflozin integrando la evidencia clinica actual canagliflozin: Integrating current clinical evidence
ArticleAbstract: SGLT2 inhibitors (SGLT2i) have profoundly marked the aca-demics and practice in the field of endocriPalabras claves:Adverse effects, Canagliflozin, Clinical evidence, diabetes mellitus, EfficacyAutores:Alicia De Los Ángeles Morocho-Zambrano, Cajas G.M., Cobo L.C., Gutierrez Yepez M.B., Intriago J.A., Jhersson Rivadeneira Campoverde, Piiataxi N.E., Yugsi R.A.Fuentes:scopus